The round's core claim is that the AI drug discovery field has not stalled because its models are bad. It has stalled because the data those models train on is finite, biased toward commercially attractive disease targets, and increasingly exhausted.
Western Australia's (WA) biomedical sector was on show at AusBiotech 2026, with a delegation of 19 WA companies and organisations attending Australia's premier biotechnology conference in Queensland from 21 to 23 October. Led by the Department of Energy and Economic Diversification in collaboration with…
We aim to use AI to cut down drug innovation time by 30%: Bayer Pharmaceuticals CNBC We aim to use AI to cut down drug innovation time by 30%: Bayer Pharmaceuticals
HuBMAP Data Portal, Announced in Paper in Nature Communications, Links Over 9,000 Data Sets for Investigations of Human Body in 3D, and Scales from Organs to Cells Future goals for the HuBMAP Data Portal include further development to make it and its…
A view inside SK Biopharmaceuticals’ research and corporate headquarters in Pangyo, Seongnam, Gyeonggi Province / Courtesy of SK Biopharmaceuticals SK Biopharmaceuticals, a Korean firm focused on developing original prescription drugs, has built a massive artificial intelligence (AI) dataset of more than…
Bioengineer.org Machines Join the Hunt for New Schistosomiasis Drugs Subject of Research: How automation and machine learning can accelerate drug discovery for schistosomiasis, a neglected tropical disease treated with a single decades-old drug. Article Title: Automation and machine learning…
By Brian Buntz | November 5, 2026 In a Nov. 4 interview with R&D World, Schnall-Levin predicted that some parts of developing therapies and diagnostics “will get massively accelerated” while others “will still be really painfully slow.” He is still working out which…
HuBMAP Data Portal, Announced in Paper in Nature Communications, Links Over 9,000 Data Sets for Investigations of Human Body in 3D, and Scales from Organs to Cells Future goals for the HuBMAP Data Portal include further development to make it and its…
Silicon Valley may be talking about AI erasing disease within a decade, but the Wall Street Journal reports that the people actually making drugs aren't exactly on board.... Drug CEOs Balk at AI Hype on New Drugs Silicon Valley may…
Targets, biomarkers, AI discovery, and Phases I–III clinical results.
An article joins this feed when it matches these terms. Each one is also a search of its own.